April 28, 2026
For many years, individuals with high-risk non-muscle invasive bladder cancer (NMIBC) whose disease did not respond to bacillus Calmette-Guerin (BCG) therapy were often left with limited choices. For most patients, the next recommended step was removal of the bladder, a surgery known as radical cystectomy.
While this operation can provide excellent cancer control, it is a major life event that can affect daily quality of life. In recent years, however, the treatment landscape for patients with BCG-unresponsive disease has evolved considerably. Several new bladder-sparing therapies have emerged, offering additional approaches for managing the disease without immediately resorting to bladder removal.
"The pace of innovation in BCG-unresponsive bladder cancer has been remarkable. We now have multiple therapies with different mechanisms that allow us to sequence treatments and help many patients preserve their bladders. It's an exciting time because we can increasingly offer cancer control while maintaining quality of life," says Paras H. Shah, M.D., a bladder cancer specialist at Mayo Clinic in Rochester, Minnesota.
These newer treatments attack cancer in different ways. Some are designed to stimulate the body's immune system to recognize and destroy tumor cells. Others deliver chemotherapy directly into the bladder. Certain therapies rely on gene-based technology to enhance the body's own anticancer defenses. Because each option works through a distinct biological pathway, physicians can often try another treatment if the first one stops being effective. This creates the opportunity to sequence therapies and potentially maintain bladder function for longer periods of time.
One commonly used bladder-preserving approach is the intravesical combination of gemcitabine and docetaxel. These chemotherapy medications are placed directly into the bladder using a catheter and act directly against cancer cells by interfering with their DNA and ability to divide. It is a very well tolerated and safe treatment because it is put directly into the bladder and does not get into the bloodstream. Clinical studies have reported encouraging outcomes, with roughly 60% of patients remaining free of recurrence one year after treatment and about 40% maintaining that response at two years.
Another development is nadofaragene firadenovec, the first gene-based therapy approved for bladder cancer. This treatment uses a modified virus to deliver genetic instructions to cells lining the bladder. Once inside the cells, these instructions lead to the production of interferon-alpha, a protein that helps activate the immune system to attack cancer. The therapy is given directly into the bladder, typically once every three months. In clinical trials, just over half of patients achieved a complete response within three months, and many of those individuals maintained their response for at least a year.
A more recent immunotherapy option is nogapendekin alfa inbakicept, which is administered alongside BCG. This medication stimulates the interleukin-15 pathway, which activates key immune cells, including natural killer cells and CD8-positive T cells. By boosting these components of the immune system, the therapy enhances the body's ability to detect and eliminate bladder cancer cells. Clinical trials have demonstrated complete response rates in the range of 60% to 70%, with many patients maintaining their responses for longer than a year.
Complete response outcomes by therapy
The most recent addition to the armamentarium for treatments of BCG-unresponsive bladder cancer is TAR-200, a novel drug-delivery system designed for use inside the bladder. The device, which is inserted through a catheter, slowly releases the chemotherapy drug gemcitabine over a period of about three weeks. During that time, the medication continuously bathes the bladder lining, providing sustained exposure to the cancer cells while minimizing systemic side effects. The extended release of chemotherapy may enhance its effectiveness against tumors. In clinical studies, approximately 82% of patients experienced a complete response, and about half remained cancer-free for at least one year.
One of the most encouraging aspects of these advances is that they provide multiple potential lines of therapy. If a patient does not respond to one treatment, another with a different mechanism may still be successful. This growing set of options allows physicians to tailor treatment strategies and increases the likelihood that patients can preserve their bladders while still effectively managing their cancers.
As research continues and additional therapies become available, patients with BCG-unresponsive NMIBC now have more treatment possibilities than ever before. What was once a situation with few alternatives is gradually becoming a landscape where bladder preservation is increasingly realistic.
For more information
Refer a patient to Mayo Clinic.